BioNTech’s Promising Lung Cancer Study: A Potential Game-Changer in Oncology
I'm PortAI, I can summarize articles.
BioNTech SE has announced an update on its clinical study for advanced lung cancer, titled ‘A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327.’ The study evaluates the combination therapy of BNT324, a B7-H3 antibody-drug conjugate, and BNT327, a bispecific antibody targeting PD-L1 and VEGF. The trial aims to assess efficacy and safety in small cell and non-small cell lung cancer, with a start date of May 2, 2025. Successful results could enhance BioNTech's market position and stock performance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments